The Lindsay-based firm has seen family courts move to virtual hearings, fights among divorced couples over child custody and in-person schooling during quarantine, and an increase in separations and divorces from couples struggling during lockdown.
“The coronavirus pandemic has caused some of the biggest changes in family law that we’ve ever seen in a single year,” said founder Russell Alexander. “We’ll be seeing the long-term effects of this for years to come.”
The firm’s lawyers saw the changes almost immediately, as quarantine rules shut down courtrooms and forced lawyers to begin meeting with clients virtually using videoconferencing software like Zoom.Lockdowns also began to complicate existing custody arrangements, as divorced parents fought over visitation, traveling and managing home school.
Alexander said that the tension among spouses who were forced to spend most of the last year together at home, with few opportunities for going out or seeing friends and family also took a toll on marriages.
“We’ve gotten a lot more inquiries than usual from couples who are considering divorce after the pandemic,” he said. “The intensity of the last year has pushed some already-troubled marriages to the brink.”
Looking ahead, Alexander said that he expects family courts to continue holding some hearings virtually because they are convenient, while custody arrangements may even include some provisions for how to respond to future pandemics.
***
Russell Alexander Collaborative Family Lawyers Russell Alexander Collaborative Family Lawyers is committed to practicing exclusively in the area of family law in Ontario dealing with all aspects, including separation and divorce, child custody and access, spousal support, child support, and division of family property. A team of lawyers provide guidance from start to finish, helping clients identify and understand the legal issues as well as the options and opportunities available through the transition. The firm has offices in Lindsay, Whitby, Oshawa, Markham, Peterborough and Toronto, Ontario. For more information, visit: http://www.russellalexander.com.
Stix Brands International Launches Frontline Protection Kits in Support of Brain Injury Canada
TORONTO, March 17, 2021 /CNW/ - Stix Brands International has officially launched their "Tools for the Rules" Campaign in support of Brain Injury Canada (BIC).
This initiative introduces personal Frontline Protection Kits available for purchase to protect you, your family and others from COVID-19. Each Kit contains:
5 PPE Health Canada-Approved masks;
2 personal SoapStix hand wash sprays;
1 personal SoapStix hand sanitizer spray.
Each Kit costs $19.99 plus applicable taxes; your purchase helps support the services and treatment of the 165,000 Canadians who suffer from traumatic Brain Injuries every year.
For every Kit sold, Stix Brands will donate $4 to Brain Injury Canada.
Stix Brands International was founded following the SARS and H1N1 outbreak to provide portable and practical solutions to help prevent the spread of germs and to increase access to personal hygiene. Our products use 100% natural ingredients that protect and soothe skin while eliminating germs. Our goal is to provide individuals with access to skin care protection everywhere they go. www.stixbrandsinternational.com
About Brain Injury Canada (BIC):
Brain Injury Canada is a national charitable organization focused on education; advocacy and awareness of acquired brain injury. The stats around brain injury are pretty staggering and demonstrate the prevalence of brain injury across the nation. Traumatic brain injury (TBI) can impact every part of a person's life - cognitively, physically, emotionally and behaviourally. TBI's are caused by something that comes from outside the body. This includes blows, bumps, and jolts to the head.
Traumatic brain injury (TBI) is a leading cause of disability globally. TBI occurs at an annual rate of 500 out of 100,000 individuals. That is approximately one person injured every 3 minutes in Canada.
Health Canada approves new indication for lung cancer treatment option ALUNBRIG®
First-line indication offers Canadians with advanced lung cancer new treatment options
TORONTO, March 17, 2021 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has issued ALUNBRIG® (brigatinib tablets) marketing authorization without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).1 The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and showed that once-daily ALUNBRIG® was superior to crizotinib on measures of efficacy and tolerability making it a promising first-line treatment option.2
"This is important news for Canadians living with ALK+ locally advanced or metastatic non-small cell lung cancer. New treatment options are essential to support patients on their journey. Having access to clinically evaluated therapies provides choices to stay ahead of cancer," said Dr. Geoffrey Liu, Senior Scientist, Princess Margaret Cancer Care Centre, University Health Network. "This new indication will be crucial to improving the health of Canadians impacted by ALK+ locally advanced or metastatic NSCLC. I look forward to sharing this positive announcement with patients."
Non-small cell lung cancer is the most common form of lung cancer, accounting for approximately 80 to 85 per cent of lung cancers diagnosed in Canada each year.3 There are many different subtypes of NSCLC that start in the different types of cells and tissues of the lung. ALK+ is a subset of NSCLC, often striking people at a younger age, many of whom have never smoked.4 Studies indicate that chromosomal rearrangements in the ALK gene is a key driver in this subset of NSCLC patients. Between three to five per cent of patients diagnosed with locally advanced or metastatic NSCLC test positive for the ALK gene rearrangement.5
"The approval of ALUNBRIG® is a significant step forward for Canadians battling advanced forms of lung cancer, who now have a new treatment option available in their fight against a devastating disease," says David Fyshe, Oncology Country Head, Takeda Canada. "We are proud of ALUNBRIG® clinical results demonstrating first-line treatment benefits. This new oncology indication directly supports Takeda's on-going commitments to uncover solutions for people living with cancer."
In 2018, ALUNBRIG® (brigatinib) was issued marketing authorization with conditions, pending the results of trials, as a monotherapy for the treatment of adult patients with ALK+ metastatic NSCLC who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).
About the Phase 3 ALTA 1L Trial
The safety and efficacy of brigatinib was evaluated in a, Phase 3 open-label, multicenter trial (ALTA 1L) in 275 adult patients with advanced ALK+ NSCLC who had not previously received an ALK-targeted therapy with a documented ALK rearrangement based on a validated ALK testing. Patients could have up to 1 prior regimen of systemic anticancer therapy in the locally advanced or metastatic setting and had an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. The major efficacy outcome measure was progression-free survival as evaluated by a Blinded Independent Review Committee (BIRC).
About ALUNBRIG® (brigatinib)
ALUNBRIG® is a targeted medicine that blocks the action of the altered ALK gene to help shrink or slow cancer growth. ALUNBRIG® is administered orally, beginning with seven days of 90 mg once daily, followed by 180 mg once daily thereafter. ALUNBRIG® is now indicated as a monotherapy for the first-line treatment of adult patients with ALK+ locally advanced (not amenable to curative therapy) or metastatic NSCLC and as a monotherapy for the treatment of adult patients with ALK+ metastatic NSCLC who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).1
ALUNBRIG® and the ALUNBRIG Logo® are registered trademarks of ARIAD Pharmaceuticals, Inc.
About Takeda Canada Inc.
Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Additional information about Takeda Canada is available at www.takeda.com/en-ca.
References
1 ALUNBRIG® Product Monograph. Date of Revision March 2, 2021. Available at https://www.takeda.com/4a4cc3/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/alunbrig/alunbrig-pm-en.pdf. Accessed March 2021. 2 Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11. PMID: 32780660; PMCID: PMC7605398. Accessed March 2021. 3 Canadian Cancer Society. Malignant tumours of the lung. Available at http://www.cancer.ca/en/cancer-information/cancer-type/lung/lung-cancer/cancerous-tumours/?region=on. Accessed February 2021. 4 Gridelli, et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014;40(2): 300–306. 5 Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19(15):4273-81.
SOURCE Takeda Canada Inc
With a Two-Year Revenue Growth of 433%, Eosera®, Inc. Ranks No. 25 on Inc. Magazine’s List of the Fastest-Growing Private Companies in Texas
Companies on the 2021 Inc. 5000 Regionals: Texas list employed more than 44,000 people.
Fort Worth, TX, March 17th, 2021 -Inc. magazine today revealed that Eosera®, Inc. is No. 25 in Texas and No. 1 in Fort Worth on its second annual Inc. 5000 Regionals: Texas list, the most prestigious ranking of the fastest-growing Texas-based private companies. Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Texas economy’s most dynamic segment—its independent small businesses.“It’s an honor to be included on the list, and we’re proud of Eosera’s growth and success over the past years. With a mix of hard work, luck, and opportunity, Joe and I founded a successful, amazing company with a wonderful culture and great team members,” says Elyse Dickerson, CEO.Elyse Dickerson and Joe Griffin, cofounders of Eosera, Inc., which ranks No. 25 on Inc. magazine’s list of the fastest-growing private companies in Texas.Complete results of the Inc. 5000 Regionals: Texas, including company profiles and an interactive database that can be sorted by industry, metro area, and other criteria, can be found at https://www.inc.com/inc5000/regionals/texas.“This list proves the power of companies in Texas no matter the industry,” says Inc.editor-in-chief Scott Omelianuk. “The impressive revenues and growth rates prove the insight and diligence of CEOs and that these businesses are here to stay.”Eosera’s comprehensive line of ear care products are available in over 13K retail stores.About EoseraEosera®, Inc. is a female-led biotech company that addresses underserved healthcare needs. Focused on ear care, Eosera was founded in 2015 by cofounders Elyse Dickerson and Joe Griffin. Eosera manufactures their products in Fort Worth, Texas, practices conscious capitalism, and sticks to their core values as a company. With products in over 13K stores, Eosera always puts people before profits and creates quality products for consumers addressing earwax blockage, ear hygiene, ear itch, and ear irrigation. The company’s fastest-growing products are EARWAX MD® and WAX BLASTER MD®. Eosera is proud to be everything ear care and proud to be creating the latest ear care innovations in decades. For more information, visit http://www.eosera.com/inc5000.More about Inc. and the Inc. 5000 RegionalsMethodologyThe 2021 Inc. 5000 Regionals are ranked according to percentage revenue growth when comparing 2017 and 2019. To qualify, companies must have been founded and generating revenue by March 31, 2017. They had to be U.S.-based, privately held, for profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2019. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2017 is $100,000; the minimum for 2019 is $1 million. As always, Inc. reserves the right to decline applicants for subjective reasons.
Learn How to Unlock Your Inner Creative Genius
Philadelphia, PA, March 17, 2021 — What is creative genius, where does it come from and, perhaps more importantly, how can we cultivate it in ourselves?
In his groundbreaking new book, Higher Self Expression: How to Become an Artist of Possibility, meditation teacher and mystical philosopher Jeff Carreira explores the answers to these questions and more through a sweeping exploration of the nature of spiritual genius and the profound state of inner freedom that unleashes it.
“In this book, you will discover that genius is not only a talent that you are born with, but also a human capacity that can be trained and cultivated by anyone,” Carreira says.
He examines the unusual lives of luminaries such as Gertrude Stein, Ralph Waldo Emerson, William James, Anaïs Nin, Philip K. Dick and Captain Marvel, and compares the genius of Eastern mysticism with the brilliance of Christianity and Islam.
“You will explore great works of poetry, literature, science fiction, comic books and even extreme sports,” Carreira adds. “You will learn how to develop your own capacity for genius by discovering a mysterious inner state of mind that is intimately connected to life and simultaneously free of limitations and boundaries.”
With a foreword by Jeffrey J. Kripal, J. Newton Rayzor Chair in Philosophy and Religious Thought at Rice University, Higher Self Expression will illuminate your own potential for genius through open-minded sensitivity, which Carreira says can be learned, practiced and mastered.
Jeff Carreira is a meditation teacher, mystical philosopher and author of 14 previous titles, who works with a growing number of people throughout the world. He offers retreats and courses guiding individuals in a form of meditation he refers to as The Art of Conscious Contentment. He creates courses and programs that encourage people to question their most foundational experience of reality until previously held assumptions fall away, leaving space for a dramatically new understanding to emerge.
In his books and lectures, he explores revolutionary ideas in the domains of spirituality, consciousness and human development. He is passionate about the potential ideas have to shape how we perceive reality and how we live together. His enthusiasm for learning is infectious, and he has taught at colleges and universities throughout the world. His other books include American Awakening, Philosophy Is Not a Luxury, The Soul of a New Self, Paradigm Shifting and The Art of Conscious Contentment.
Major Depressive Disorder: The Hope-Filled Battle for the Causes and the Cures
Spokane, WA, March 17, 2021 — The voice on the other end of the phone was familiar but shaky. It was Sarah’s friend Carolyn, and she was grappling with suicidal ideation.
“Something had her in its grip and would not let go,” Sarah Zabel explains. “I kept wondering, what’s doing this? How does a normal, happy person come to feel life is so bad that she must kill herself?”
A decade after that first phone call, solutions for Carolyn’s major depressive disorder remained elusive, and Sarah felt compelled to understand why.
Fighting Chance: How Unexpected Observations and Unintended Outcomes Shape the Science and Treatment of Depression delivers a 360-degree look inside the world of this debilitating illness, featuring interviews with more than 20 experts in the fields of neuroscience and psychiatry, current research and the unforgettable stories of 16 people personally impacted by depression.
Described by Sarah as a “science book for non-scientists,” Fighting Chancetackles key questions that have guided scientific research for decades and delves into the discoveries that have formed the medical world’s understanding of the disorder. Peppered throughout are more than 20 illustrations that help explain the science involved — making it widely accessible.
Sarah adeptly explores topics ranging from the neurobiology of depression to antidepressant medications; stress and inflammation; genetics; suicide; traditional and alternative therapies and treatments; and even gives a nod to Big Data’s efforts to clarify depression’s causes and cures.
Ultimately, Fighting Chance is a tale of human endeavor and ingenuity, of downright weird experiments and serendipitous discoveries, and of people who valiantly battle for answers for themselves and for people they will never know.
Author Sarah Zabel graduated from the U.S. Air Force Academy with a degree in computer science in 1987 and was commissioned a second lieutenant. She retired from the Air Force in 2018 as a major general and decided to turn her focus to her life-long love of learning and become a science writer. She set herself the task of first coming to understand, and then to explain for other lay-persons, the science behind some of life’s most complex but important human experiences. Inspired, intrigued and frustrated by an enduring friend’s battle with depression, she set that topic as her first task. Sarah does occasional consulting and other activities associated with her time as one of the military’s leaders in cyberspace operations and security, in the provision of communications and other services to a community, and leadership of a diverse workforce.
Journalist & Political Pundit Sophia Nelson Re-Releases The Woman Code to Inspire Women during COVID
Morning Joe Host & Author of Know Your Value, Mika Brzezinski, Pens Foreword
Washington, D.C., March 17, 2021 — The world has faced unprecedented challenges from the coronavirus pandemic, but it has hit women harder personally and financially, as they juggle multiple roles as professionals, caretakers, mothers and wives—simultaneously.
“Women are the soul of what keeps the world going. We keep our families, our companies, our communities and our nations intact,” explains Sophia A. Nelson, acclaimed journalist and author of The Woman Code: 20 Powerful Keys to Unlock Your Life (April 2021, Health Communications).
Named one of the most inspirational books by Woman’s Day in 2015-2017, this transformative book is updated with new insights about the profound economic and societal shifts that have changed our world since the pandemic. Nelson guides women through living out a powerful life Code that will lead them to purposeful, meaningful and authentically successful lives.
Every woman lives by a Code, whether she realizes it or not. It informs how she treats herself and others and how far she is willing to go in order to find success. Nelson calls on women to examine whether the Code they’re living by is truly helping them create the lives they desire. A senior columnist for USA Today and a frequent commentator on CNN, Nelson reveals 20 powerful Codes including:
Know Your Value
Be Resilient
Choose Your Thoughts and Words Wisely
Lift Other Women as You Climb
Practice Love, Laughter, Loyalty
With life quotes from philosophers and poets, mystics and her maternal grandmother, plus her experience as a Black woman rising through the ranks of a male-dominated news industry, The Woman Code is an essential tool of transformation for women to enjoy in reading groups, retreats and Bible study groups. It will help women honor themselves while navigating the demands of work, home, family and friendship no matter what their age or stage in life.
About the Author
Sophia A. Nelson is an award-winning American author and journalist who appears regularly on CNN’s Inside Politics and Newsroom as a legal and political analyst. She is an adjunct professor in the Department of Philosophy and Religion at Christopher Newport University in Newport News, Virginia.
Nelson covered former First Lady Michelle Obama at the White House from 2010–2012. The author appears frequently on CNN and has been a contributor to MSNBC, NBC, Fox News, the BBC, ABC World News with Diane Sawyer and the Today show. She writes for The Huffington Post Healthy Living and The Daily Beast. She has also contributed to USA Today, Essence, The Wall Street Journal, The New York Times and The Washington Post. She is the author of The Woman Code, Black Woman Redefined, and E Pluribus ONE.
The Woman Code: 20 Powerful Keys to Unlock Your Life
Post-Traumatic Thriving Shares Essential Elements for Authentic Healing
Los Angeles, CA, March 17, 2021 — Trauma has a way of showing up when we least expect it, and society sends many signals telling us that it’s admirable to put on a brave face and soldier on. But our grief is normal — even healthy, says world-renowned expert on disasters and trauma Dr. Randall Bell.
“The hallmark error is to continually dodge the pain. There is a time and place for avoidance. However, to heal and grow, we cannot doge the pain forever …,” he writes in his new book, Post-Traumatic Thriving: The Art, Science, & Stories of Resilience. “Suffering is our opportunity to stare our moral compass in the eye and deal with the problem in a dignified way.”
Dr. Bell undertook unprecedented research, and juxtaposes outcomes of scientific studies with stories of real people (many of them familiar) who have used their trauma as their fuel to thrive to reveal common denominators. He divides his remarkable insights into three sections: The Dive Stage, The Survive Stage and The Thrive Stage, and outlines a step-by-step process toward authentic healing.
To inspire and connect with readers who’ve experienced trauma, he shares stories of remarkable resilience, including the following:
• A deaf man with a glass eye invented the electric guitar and became a household name, remarkably wealthy and most importantly, happy.
• A convicted murderer took responsibility for the damage he caused, graduated with honors from college, became a minister and turned around the hearts of the most hardened criminals.
• A girl born with cerebral palsy landed the world’s first starring role on national television and spoke at the White House three times.
• A woman hid in a basement for years and lost her entire family in the Holocaust. She eventually found true love and paints stunning artwork.
• The sister of a murder victim helped millions of women in toxic domestic relationships.
• A woman’s car crash resulted in an addiction to prescription drugs, a divorce, a loss of her children and a cot in a homeless shelter. She has rebuilt it all back and more.
• A man set to go to the Olympics had his hopes dashed by Jimmy Carter and went on to build a worldwide business empire.
Ultimately, Dr. Bell documents the science of happiness, as well as the individual styles and common thread that all post-traumatic thrivers have to emerge with a fulfilling life. When trauma hits, your most significant decision will be to dive, survive or thrive. If you choose to thrive, this book is for you.
As an economist, Dr. Randall Bell has consulted on more disasters on earth than anyone in history and is widely considered the world’s top authority in the field of post-traumatic thriving. His clients include the Federal Government, State Governments, International Tribunals, major corporations and homeowners. Dr. Bell believes that “the problem is not the problem — the problem is how we react to the problem.”
Often called the “Master of Disaster,” Dr. Bell is squarely focused on authentic recovery and resilience. His research has been profiled on major television shows and featured in numerous magazines and the international media. More information can be found at www.posttraumaticthriving.com.
Post-Traumatic Thriving: The Art, Science, & Stories of Resilience
THYMOX EXT botanical disinfectant kills the COVID-19 virus in only 1 minute
SHERBROOKE, QC, March 17, 2021 /CNW Telbec/ - Canadian company Laboratoire M2's THYMOX brand spray disinfectant is one of the only products made with a botanically derived active ingredient, officially approved by Health Canada for use against the SARS-CoV-2 virus that causes COVID-19. Official tests prove that THYMOX EXT kills SARS-CoV-2 virus in 1 minutes on hard surfaces.
With the convincing results of THYMOX disinfecting and cleaning solution, Laboratoire M2 is among the first Canadian companies to manufacture and offer the industrial and institutional markets an alternative to traditional chemical products. "We've been working for many years to develop products with proven results that can rival those of leading brands. Our THYMOX disinfectant spray - made from botanically derived products - is as effective as other products on the market and can contribute to the fight against the novel coronavirus", underlines Geneviève Legault, Product Development and Marketing Manager.
Technology behind THYMOX
THYMOX technology is based on the proven efficacy of thymol, a botanically derived active ingredient. It is made with over 98% renewable ingredients, is biodegradable, has a low toxicity profile and demonstrated effectiveness against the COVID-19 virus. "Consumers appreciate its lower toxicity and its disinfecting power while being an excellent cleaner, in just one step", adds Mme Legault. The growing demand and sales of our disinfectants across North America prove this. "We're very proud to be cutting edge and to do our part in the fight against SARS-CoV-2 virus without affecting the environment."
About Laboratoire M2
Laboratoire M2 Inc, based in Sherbrooke, Quebec, Canada, has an excellent reputation for innovation and expertise in environmentally responsible and sustainable disinfection and biosecurity technology products under the THYMOX® brand. The company markets a range of biodegradable, high-performance and safe antimicrobial products based on its technology platform in three business units. Animal health products, which include THYMOX HOOF®, which is used to control the spread of bacteria that cause digital dermatitis (DD). In the area of agricultural crop protection, LM2 products are sold in the United States and Canada under the THYMOX CONTROL® and THYMOX Gro® brands. For the commercial and retail markets, THYMOX® technology is used in surface disinfection and distributed through various global agreements.
For more information about Laboratoire M2, visit www.thymox.com.
SOURCE Thymox
8 Key Traits that Can Attract Others and Boost Your Self-Image
New York, NY, March 17, 2021 — Attraction, that mysteriously magnetic pull toward another human being, is notoriously difficult to quantify and qualify. What is it exactly that makes you want to be near someone and give them your time, your energy, your attention, your affection and even your respect? And how can you make others feel that way toward you?
Author Justin Clottey explores the complex concept of attraction and distills it into eight key “attractive” character traits in his new book, Improve Your Self-Image by Understanding What Makes Someone Attractive.
“Whether we wish to admit it or not, the image other people have of us greatly affects how we see ourselves,” Clottey says. “Why? It dictates how we are treated in the world. It’s like feedback. If it’s positive, we’re on the right track. If it’s negative, something about us might be off.”
Clottey isn’t referring to unfounded mistreatment related to culture, race, gender, age and other factors beyond our control. He’s talking about how others react to what we do and don’t do; what we say and don’t say; and how the way we present ourselves impacts every type of relationship we have, including with romantic partners, friends, bosses, coworkers, business partners and clients.
Improve Your Self-Image is a concise yet comprehensive guide that explores in detail Clottey’s eight key factors of attractiveness — Certainty, Ease, Balance, Brevity, Mastery, Lightheartedness, Reputation and Physical Appearance — and how we can apply this understanding of attraction to improve the way we communicate and associate with others to better navigate our relationships going forward.
Author Justin Clottey was born in the United States and has spent different periods of his life in various cities within Canada and around the world.
Clottey considers himself to be a lifelong learner. Having an interest in constantly improving every area of his life, he is always looking for the best ways to do just that. The world of writing books to help people improve their own lives is an outlet he uses to live out his passion for teaching. As an elementary school teacher, he enjoys sharpening his talent for breaking down complex concepts into small, digestible pieces for his learners.
He has passions for fitness, sports and language learning, and speaks fluent English, Spanish and French. He also enjoys spending time with friends and family as well as exploring different places.
Follow Justin Clottey on Instagram at @becomextraordinary.
Improve Your Self-Image by Understanding What Makes Someone Attractive
ISBN-10: 1777430518
ISBN-13: 978-1777430511
Available in print, eBook or audio format from Amazon.com, Apple Books, Google Play and other online outlets
###
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
Elyse Dickerson and Joe Griffin, cofounders of Eosera, Inc., which ranks No. 25 on Inc. magazine’s list of the fastest-growing private companies in Texas.Complete results of the Inc. 5000 Regionals: Texas, including company profiles and an interactive database that can be sorted by industry, metro area, and other criteria, can be found at 
Eosera’s comprehensive line of ear care products are available in over 13K retail stores.About Eosera
